Clinical Trials

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT01886872 2026-04-13

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

547 enrolled 19 charts

Phase 1 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03220022 2026-04-13

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

46 enrolled 19 charts

Lymphoma, AIDS-Related

NCT03462719 2026-04-13

GLOW

211 enrolled 23 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03737981 2026-04-13

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

465 enrolled 11 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02477696 2026-03-27

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

533 enrolled 18 charts

Phase 1 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02446236 2026-03-24

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

27 enrolled 11 charts

Lymphoma, Mantle-Cell

NCT02947347 2026-03-17

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

Phase 3 Completed

445 enrolled 18 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT03506373 2026-03-05

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Phase 2 Terminated

21 enrolled 11 charts

Waldenstrom Macroglobulinemia

NCT03514017 2026-03-02

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Phase 2 Terminated

5 enrolled 11 charts

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02649387 2026-02-10

MERIT

Phase 2 Completed

35 enrolled 7 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03204188 2026-01-30

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2 Completed

15 enrolled 9 charts

Phase 1/2 Active not recruiting

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02427451 2026-01-27

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

87 enrolled 30 charts